Related Experiment Video
Updated: Jun 24, 2026

In Silico Clinical Trials for Cardiovascular Disease
Published on: May 27, 2022
[CADASIL and CARASIL].
1Departamento de Anatomía Patológica, Hospital de Cruces, Universidad del País Vasco, Barakaldo, Bizkaia. joseignacio.lopez@ehu.es
Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) and cerebral autosomal recessive arteriopathy with subcortical infarcts and leucoencephalopathy (CARASIL) are rare genetic vascular diseases. This review covers their genetic, clinical, and pathological distinctions.
Area of Science:
- Neurology
- Genetics
- Pathology
Background:
- Cerebral autosomal dominant arteriopathy with subcortical infarcts and leucoencephalopathy (CADASIL) is a genetic vascular disorder linked to NOTCH3 gene mutations.
- Cerebral autosomal recessive arteriopathy with subcortical infarcts and leucoencephalopathy (CARASIL) is a less understood hereditary vascular disease with unidentified genetic cause.
- Neither condition is associated with hypertension.
Purpose of the Study:
- To review the genetic, clinical, and pathological aspects of CADASIL and CARASIL.
- To highlight the differences between these two rare arteriopathies.
Main Methods:
- Literature review of genetic, clinical, and pathological findings for CADASIL and CARASIL.
- Comparative analysis of disease characteristics.
Main Results:
- CADASIL presents with migraines, strokes, cognitive decline, and specific arterial lesions, linked to NOTCH3 mutations.
- CARASIL is characterized by strokes, bone lesions, and alopecia, with an unknown genetic basis.
- Both are hereditary arteriopathies distinct from hypertensive cerebrovascular disease.
Conclusions:
- CADASIL and CARASIL represent distinct genetic arteriopathies affecting the brain.
- Understanding these differences is crucial for diagnosis and management of rare hereditary cerebrovascular diseases.
Related Concept Videos
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Imaging Studies for Cardiovascular System VI: Calcium -Scoring CT
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease V: Interprofessional Care